Abstract
This review discussed the role of gastric emptying and its related glucagon-like peptide-1(GLP-1)releasing in maintaining glucose homeostasis, and further illustrated the efficacy and safety of short-acting GLP-1 receptor agonists(GLP-1 RAs), such as Lixisenatide in treating type 2 diabetes. The cardiovascular effects of GLP-1 RAs were also reviewed. This article is the Chinese translation of Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus [Expert Opin Drug Metab Toxicol, 2017, 13(3): 311-321]which was published in March 2017, with the permission from the journal(Taylor & Francis Group). (Chin J Endocrinol Metab, 2017, 33: 1075-1082) Key words: Diabetes mellitus, type 2; Glucagon-like peptide-1 receptor agonists; Lixisenatide
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
